Penicillin Allergy Delabeling Program: an exploratory economic evaluation in the Australian context

被引:9
|
作者
Brusco, Natasha K. [1 ,2 ]
Bury, Susan [3 ,4 ]
Chua, Kyra Y. L. [3 ]
Vogrin, Sara [5 ]
Holmes, Natasha E. [3 ,6 ,7 ,8 ]
Trubiano, Jason A. [3 ,9 ,10 ,11 ]
机构
[1] Monash Univ, Alpha Crucis Grp, Hlth Econ, Clayton, Vic, Australia
[2] Monash Univ, Rehabil Ageing & Independent Living RAIL Res Ctr, Clayton, Vic, Australia
[3] Austin Hlth, Dept Infect Dis, 145 Studley Rd, Heidelberg, Vic 3084, Australia
[4] Austin Hlth, Dept Pharm, Heidelberg, Vic, Australia
[5] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia
[6] Univ Melbourne, Dept Med & Radiol, Melbourne, Vic, Australia
[7] Austin Hlth, Data Analyt Res & Evaluat DARE Ctr, Heidelberg, Vic, Australia
[8] Univ Melbourne, Melbourne, Vic, Australia
[9] Univ Melbourne, Austin Hlth, Dept Med, Melbourne, Vic, Australia
[10] Peter MacCallum Canc Ctr, Dept Infect Dis, Melbourne, Vic, Australia
[11] Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Melbourne, Vic, Australia
关键词
Antibiotics; Delabeling; Health Economics; Health Service Research; COST-EFFECTIVENESS; HEALTH;
D O I
10.1111/imj.15532
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Internationally, clinical and economic advantages of low-risk penicillin delabelling have been explored, supporting changes to healthcare delivery systems where penicillin delabelling is embedded into inpatient usual care. Aims To determine if economic advantages of low-risk inpatient penicillin delabelling, described in the international literature, are realised in the Australian context. Methods This explorative economic evaluation had prospective patient data collection between January and August 2019, across two Australian health services. Part 1: determine the cost per effectively delabelled patient for Penicillin Allergy Delabeling Program inpatients (PADP cohort) compared with Outpatient Antibiotic Allergy Testing Service outpatients (OAATS cohort). Part 2: a cost analysis to compare hospital costs for inpatients with low-risk penicillin allergy who did (PADP cohort) and did not (usual care cohort) undergo PADP delabelling. Results Part 1: the PADP (n = 350) and OAATS (n = 27 patients, n = 36 individual visits) cohorts were comparable. In PADP, costs/proportion delabelled was $20.10/0.98, equating to $20.51 per effectively delabelled patient; in OAATS, it was $181.24/0.50, equating to $362. Compared with OAATS, PADP was associated with savings of $341.97 per effectively delabelled patient, indicating the outpatient testing was the dominated strategy, being more costly and less effective. Part 2: the PADP (n = 218) and usual care (n = 32) cohorts were comparable. Significantly favouring the delabelled PADP cohort, the mean difference per patient was -4.41 days (95% confidence interval: -7.64, -1.18) and -$9467.72 (95% confidence interval: -$15 419.98, -$3515.46). Conclusions Consistent with international literature, delabelling low-risk penicillin allergies in the inpatient setting had economic advantages in the Australian context. Fully powered economic evaluations are urgently required to consolidate these findings.
引用
收藏
页码:74 / 83
页数:10
相关论文
共 50 条
  • [1] Evaluation of a Pharmacist-Led Penicillin Allergy Assessment Program and Allergy Delabeling in a Tertiary Care Hospital
    Turner, Nicholas A.
    Wrenn, Rebekah
    Sarubbi, Christina
    Kleris, Renee
    Lugar, Patricia L.
    Radojicic, Christine
    Moehring, Rebekah W.
    Anderson, Deverick J.
    JAMA NETWORK OPEN, 2021, 4 (05)
  • [2] Delabeling Without Testing in a Pharmacy-led Inpatient Penicillin Allergy Evaluation Program
    Brown, Jordana
    Kaddis, Timothy
    Ham, YoungYoon
    Joshi, Shyam
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB40 - AB40
  • [3] Update on penicillin allergy delabeling
    Shaker, Marcus
    McWilliams, Samuel
    Greenhawt, Matthew
    CURRENT OPINION IN PEDIATRICS, 2020, 32 (02) : 321 - 327
  • [4] Delabeling of Penicillin Allergy: Room for Improvement
    Fransson, Sara
    Damving, Christina Monnerup
    Boel, Jonas Bredtoft
    Arpi, Magnus
    Skinhoj, Ida Gjorup
    Jarlov, Jens Otto
    Mosbech, Holger F.
    Poulsen, Lars K.
    Garvey, Lene H.
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2023, 184 (09) : 870 - 874
  • [5] Feasibility of a Centralized, Pharmacy-Led Penicillin Allergy Delabeling Program
    Antoon, James W.
    Grijalva, Carlos G.
    Grisso, Alison G.
    Stone, Cosby A.
    Johnson, Jakobi
    Stassun, Justine
    Norton, Allison E.
    Kripalani, Sunil
    Williams, Derek J.
    HOSPITAL PEDIATRICS, 2022, 12 (07) : E230 - E234
  • [6] Retrospective study on penicillin allergy delabeling and evaluation of an antibiotic allergy assessment tool
    Honda, Ryoko
    Ishikawa, Kazuhiro
    Ozawa, Hiroki
    Matsumoto-Takahashi, Emilie Louise Akiko
    Mori, Nobuyoshi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (01)
  • [7] Penicillin Allergy Delabeling: A Multidisciplinary Opportunity
    Staicu, Mary L.
    Vyles, David
    Shenoy, Erica S.
    Stone, Cosby A.
    Banks, Taylor
    Alvarez, Kristin S.
    Blumenthal, Kimberly G.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (09): : 2858 - +
  • [8] Effectiveness and feasibility of a penicillin allergy delabeling program in the postacute inpatient rehabilitation setting
    Galipean, Joseph
    Jacob, Jerry
    INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2024, 45 (11) : 1370 - 1372
  • [9] Penicillin Allergy Decision and Mobile Empowerment (PADME): A Novel PatientInitiated Delabeling Program
    Winslow, Andrew
    Kwan, Mildred
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB131 - AB131
  • [10] Penicillin allergy delabeling in Croatia - A pilot study
    Markovic, I.
    Lazarevic, V. Vukicevic
    Bozan, M.
    Sokolic, I.
    Prlic, M.
    Markovic, A. Stipic
    Artukovic, M.
    ALLERGY, 2023, 78